Endocrine Testing Market Size was valued at USD 12.6 Billion in 2023 and is expected to reach USD 27.2 Billion by 2032, growing at a CAGR of 8.9% over the forecast period 2024-2032.
The Endocrine testing market explores the increasing incidents of endocrine diseases to unveil the need for endocrine testing in clinical diagnosis. It analyzes testing demand and volume, highlighting growth in regions. The report examines the adoption of Immunoassays, PCR, and Mass Spectrometry. It also examines healthcare spending with a focus on government, private insurance, and out-of-pocket spending. The review encompasses global regulatory trends FDA approvals and CE markings, as well as adoption trends by region, with a particular emphasis on growth in emerging markets and improvements in healthcare infrastructure. The Endocrine Testing Market is experiencing significant growth driven by the increasing prevalence of endocrine disorders worldwide. The U.S. Department of Health and Human Services has introduced some programs to improve the screening and management of endocrine disorders which in turn is boosting the market growth.
Drivers
The rising incidence of conditions like diabetes, thyroid disorders, and obesity is a major driver for the growth of the endocrine testing market.
The rising incidence of diabetes, thyroid disorders, and obesity has led to the rapid expansion of the endocrine testing market. Diabetes has a growing incidence in India, where 31 million new cases were reported. This troubling trend is primarily due to poor diets and lack of exercise, contributing to higher obesity rates. According to the Economic Survey 2024, 54% of the disease burden in India is attributable to unhealthy diets, reflecting the dire need for preventive action. A major risk factor for both diabetes and thyroid disorders, obesity has more than tripled among adults in India. The obesity rate rose from 18.9% to 22.9% among men and from 20.6% to 24% among women, according to data released by the National Family Health Survey (NFHS). A recent study indicates that over 800 million people worldwide now have diabetes, a disease that has doubled within the last 30 years. This increase is mainly because of the growing prevalence of obesity and an aging population, emphasizing the important demand for endocrine testing and treatment. These figures highlight the importance of endocrine testing in the diagnosis and management of diseases such as diabetes, thyroid dysfunction, and obesity, which in turn is propelling the market growth.
Restraints:
The advanced testing procedures and specialized equipment required for accurate endocrine testing can be prohibitively expensive, limiting access, especially in low-income regions.
Proper endocrine testing is critical for the diagnosis and treatment of hormonal disorders. However, these tests require complicated procedures as well as specific equipment, which can be too costly and make them inaccessible particularly in low-income areas. For instance, test kits for endocrine testing alone can cost between $100 to $700–$800, making them unaffordable for many healthcare facilities in underdeveloped regions. Most developing countries have poorly established healthcare systems that rely on traditional methods of diagnostic testing. Relying on these legacy methods leads to low-quality testing, with an unreliable power supply or fluctuations in temperature impacting the accuracy of the results. Furthermore, the absence of trained personnel and quality control material reduces the credibility of the endocrine tests in these countries. The scarcity of trained endocrinologists exacerbates the situation. For example, in Sub-Saharan Africa, the estimated endocrinologist-to-population ratio is 0.03 per 100,000 people, compared to 0.89 in the Americas and 4.84 in Europe. The shortage of expert providers results in delayed diagnosis and suboptimal management of endocrine disorders, leading to increased morbidity and mortality.
Opportunities:
Advancements in genetic testing and molecular diagnostics allow for tailored treatment plans based on an individual’s genetic makeup and hormonal profile.
The evolution of genetic testing and molecular diagnostics has transformed personalized medicine, allowing for therapies individualized for a person's unique genetic makeup and hormonal composition. According to recent research, genetic screening can prevent up to 25% of premature deaths from preventable diseases such as breast cancer, diabetes, and hypertension. NHS hospitals in the UK have started a world-first trial to identify more than 200 genetic diseases in newborns using whole genome sequencing in a bid to improve diagnosis and treatment. Likewise, Genomics Australia has been instituted in Australia, to incorporate genomic medicine into a national healthcare framework, beginning with cancer care, by offering to tailor medical care to the individual characteristics of each patient, including genomic data. The India molecular diagnostics market growth is supported by growing rates of predictive medicine, early diagnosis & treatment tracking. These developments underscore the transformative potential of genetic testing and molecular diagnostics in delivering personalized, effective, and timely medical interventions, thereby improving patient outcomes and advancing healthcare globally.
Challenges:
The complex nature of endocrine systems can lead to diagnostic errors, including false positives and negatives, potentially compromising patient outcomes.
Challenges due to the complexity of the endocrine system make it a challenging task resulting in potential false positives and false negatives that may harbour consequences on patient management and outcomes. Common endocrine disorders like thyroid dysfunctions, diabetes, and adrenal imbalances are typically diagnosed through hormone-level tests in the blood. These hormone levels, however, can vary based on multiple reasons including age, medication, and even stress, making diagnosing these conditions more complicated. For example, new data from the American Thyroid Association shows that around 20 million Americans have some type of thyroid disease, but up to 60 percent are undiagnosed, in part because lab results are not being interpreted correctly. A study published in the Journal of Clinical Endocrinology & Metabolism in 2024 found that nearly 15% of those who have hypothyroidism will receive a false positive on routine screening tests and that 10% of those with the condition are misdiagnosed as having other disorders. Such test errors have the potential to lead to unnecessary treatments or missed diagnoses, which can bring serious long-term health consequences. Additionally, endocrine dysfunctions like polycystic ovary syndrome (PCOS) are frequently misdiagnosed; according to the latest findings from the Endocrine Society, about 70% of women with PCOS remain undiagnosed due to overlapping symptoms with other conditions. Because hormone regulation is complex, the reliance on high-quality, accurate diagnostic tests is essential in performing excellent care for patients.
By Test Type
The thyroid stimulating hormone (TSH) test segment dominated the market and held the largest share in terms of revenue, at 27% in 2023. The dominance can be explained with the high prevalence of thyroid disorders and the importance of TSH testing in the diagnosis and management of those diseases. There are an estimated 20 million Americans with some form of thyroid disease, and up to 60% of people with thyroid disease are unaware of their disease, according to the American Thyroid Association. The TSH test is known to have the highest sensitivity and specificity for diagnosing primary thyroid disorders and is commonly used as a first-line screening test for thyroid disease.
The recommendation from the U.S. Preventive Services Task Force to perform TSH screening among all adults aged 35 and older every five years has further spurred demand. Moreover, the growing prevalence of autoimmune thyroid diseases including Hashimoto's thyroiditis and Graves' disease has driven the segment's growth. Hashimoto’s disease, affects about 5 in 100 Americans, according to the National Institute of Diabetes and Digestive and Kidney Diseases. Owing to its high sensitivity and specificity, as well as its ability to recognize subclinical thyroid dysfunction, TSH tests have become a staple of clinical practice, forming the basis for their market leadership.
By Technology
In 2023, the tandem mass spectrometry segment dominated the market with the largest revenue share of 25% The widespread use of this technology in endocrine testing is primarily driven by its sensitivity and specificity and also by the fact that multiple analytes can be analyzed simultaneously. Tandem mass spectrometry has revolutionized the field of endocrine testing by offering superior analytical performance compared to traditional immunoassays. There has been a recent increase in the adoption of tandem mass spectrometry-based tests for common endocrine disorders by the U.S. Food and Drug Administration (FDA), which hailed their reliability and accuracy.
Newborn screening programs, which utilize tandem mass spectrometry extensively, cover 99% of all babies born in the United States, according to the Centers for Disease Control and Prevention (CDC). It enables the screening of more than 30 metabolic and endocrine disorders from a single blood spot. NIH also has put funding into research to scale up to different types of endocrine testing the same technologies of tandem mass spectrometry. For example, the Newborn Screening Translational Research Network, which is funded by the NIH, has been conducting research on new tandem mass spectrometry-based methods for expanding the panel to include additional endocrine disorders. Its dominance in the market is in part due to the performance of the technology to deliver accurate measurements of steroid hormones, thyroid hormones, and vitamin D metabolites.
By End-use
The hospitals segment held the largest revenue share at 68% in 2023. The considerable market share is attributed to the full range of hospital services, higher diagnosis capabilities, and a growing number of hospital admissions related to endocrine disease. In 2022, there were approximately 577,000 inpatient discharges with a principal diagnosis of endocrine, nutritional, and metabolic diseases in the United States, according to data from the Healthcare Cost and Utilization Project (HCUP) of the Agency for Healthcare Research and Quality.
Further, hospitals often serve as the first point of care for patients with complicated endocrine disorders as they bring multiple testing and treatment modalities to the patient under one roof. Endocrine, nutritional, and metabolic diseases constituted 7.2% (16.9 million visits) of all outpatient department visits in 2021, according to the National Hospital Ambulatory Medical Care Survey. Additionally, hospitals may have access to specialized endocrine testing platforms, such as high-tiered analyzers, skilled personnel, and space that can allow for the exclusion of interfering substances such as hemolysis, icterus, and lipemia. According to data from the Centers for Medicare & Medicaid Services (CMS), greater than 80% of complex endocrine tests were performed at hospital outpatient departments, underscoring that most complex testing occurs at the same institutions that provide advanced care.
In 2023, North America dominated the endocrine testing market with a 39% market share. The dominance of North America can be ascribed to the developed healthcare infrastructure in addition to high healthcare expenditure and the presence of key market players. The region's high prevalence of endocrine disorders also contributes to its market dominance. Another factor that contributes to the high growth of the endocrine disorder market in the region. According to the American Diabetes Association 37.3 million Americans, or 11.3% of the population had diabetes in 2023. According to the National Cancer Institute, thyroid cancer cases in the U.S. increased to 43,800 in 2023, contributing to the need for endocrine testing.
Asia Pacific region growing with the fastest CAGR over the forecast period. The rapid growth of the Asia Pacific region is attributed to rising healthcare spending, improving healthcare infrastructure, and increasing awareness regarding endocrine disorders. The World Health Organization reports that the prevalence of diabetes in Southeast Asia is expected to increase by 74% by 2045, creating a substantial market for endocrine testing. Government programs, including India's NPCDCS (National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke) are aiding the market growth by promoting early diagnosis and treatment of endocrine disorders.
Key Service Providers/Manufacturers
Abbott Laboratories (ARCHITECT i2000SR Immunoassay Analyzer, D-Cellar)
Thermo Fisher Scientific (Fisher HealthCare, Immunoassay Analyzer)
Siemens Healthineers (ADVIA Centaur XP Immunoassay System, Atellica Solution)
Roche Diagnostics (Cobas e411 Immunoassay Analyzer, Elecsys Estradiol)
Beckman Coulter (Access Immunoassay Systems, DXI 800)
LabCorp (Eclia Technology, Serum TSH Test)
Mindray (BC-6800 Chemistry Analyzer, CL-3000i Immunoassay System)
Bio-Rad Laboratories (DiaSorin LIAISON, CFX96 Real-Time PCR)
Ortho Clinical Diagnostics (VITROS ECiQ Immunodiagnostic System, VITROS 3600)
PerkinElmer (Chemagic 360, AutoDELFIA)
Key Users
Cleveland Clinic
Johns Hopkins Medicine
Mayo Clinic
Mount Sinai Health System
University of California, Los Angeles (UCLA)
Stanford Health Care
MedStar Health
Baylor College of Medicine
Children's Hospital Boston
Henry Ford Health System
Abbott Laboratories announced new FDA clearances for its automated immunoassay platform capable of improving the speed and accuracy of endocrine testing for hospital laboratories in June 2024. The system offers a comprehensive menu of endocrine tests, including thyroid, fertility, and diabetes markers.
In January 2025, Siemens Healthineers launched a software solution for AI-powered interpretation of endocrine test results, providing additional diagnostic support in complex endocrine disorders. The software is compatible with natively used laboratory information systems, and the programmed assessment has been validated in several clinical trials.
| Report Attributes | Details |
|---|---|
|
Market Size in 2023 |
USD 12.6 Billion |
|
Market Size by 2032 |
USD 27.2 Billion |
|
CAGR |
CAGR of 8.9% From 2024 to 2032 |
|
Base Year |
2023 |
|
Forecast Period |
2024-2032 |
|
Historical Data |
2020-2022 |
|
Report Scope & Coverage |
Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
|
Key Segments |
• By Test Type (Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test, Progesterone Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Testosterone Test, Cortisol Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Insulin Test, Others) |
|
Regional Analysis/Coverage |
North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
|
Company Profiles |
Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers, Roche Diagnostics, Beckman Coulter, LabCorp, Mindray, Bio-Rad Laboratories, Ortho Clinical Diagnostics, PerkinElmer. |
Ans: The projected market size for the Endocrine Testing Market is USD 27.2 Billion by 2032.
Ans: The North American region dominated the Endocrine Testing Market in 2023.
Ans. The CAGR of the Endocrine Testing Market is 8.9% During the forecast period of 2024-2032.
Ans: The major key players in the market are Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers, Roche Diagnostics, Beckman Coulter, LabCorp, Mindray, Bio-Rad Laboratories, Ortho Clinical Diagnostics, PerkinElmer., and others in the final report.
Ans:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Prevalence of Endocrine Disorders (2023)
5.2 Testing Demand and Volume (2020-2032)
5.3 Healthcare Spending on Endocrine Testing (2023)
5.4 Regulatory Landscape and Compliance (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Endocrine Testing Market Segmentation, By Test Type
7.1 Chapter Overview
7.2 Estradiol (E2) Test
7.2.1 Estradiol (E2) Test Market Trends Analysis (2020-2032)
7.2.2 Estradiol (E2) Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3 Follicle Stimulating Hormone (FSH) Test
7.2.3.1 Follicle Stimulating Hormone (FSH) Test Market Trends Analysis (2020-2032)
7.2.3.2 Follicle Stimulating Hormone (FSH) Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4 Follicle Stimulating Hormone (FSH) Test
7.2.4.1 Follicle Stimulating Hormone (FSH) Test Market Trends Analysis (2020-2032)
7.2.4.2 Follicle Stimulating Hormone (FSH) Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.5 Dehydroepiandrosterone Sulfate (DHEAS) Test
7.2.5.1 Dehydroepiandrosterone Sulfate (DHEAS) Test Market Trends Analysis (2020-2032)
7.2.5.2 Dehydroepiandrosterone Sulfate (DHEAS) Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.6 Progesterone Test
7.2.6.1 Progesterone Test Market Trends Analysis (2020-2032)
7.2.6.2 Progesterone Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.7 Human Chorionic Gonadotropin (hCG) Hormone Test
7.2.7.1 Human Chorionic Gonadotropin (hCG) Hormone Test Market Trends Analysis (2020-2032)
7.2.7.2 Human Chorionic Gonadotropin (hCG) Hormone Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.8 Luteinizing Hormone (LH) Test
7.2.8.1 Luteinizing Hormone (LH) Test Market Trends Analysis (2020-2032)
7.2.8.2 Luteinizing Hormone (LH) Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.9 Testosterone Test
7.2.9.1 Testosterone Test Market Trends Analysis (2020-2032)
7.2.9.2 Testosterone Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.10 Cortisol Test
7.2.10.1 Cortisol Test Market Trends Analysis (2020-2032)
7.2.10.2 Cortisol Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.11 Thyroid Stimulating Hormone (TSH) Test
7.2.11.1 Thyroid Stimulating Hormone (TSH) Test Market Trends Analysis (2020-2032)
7.2.11.2 Thyroid Stimulating Hormone (TSH) Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.12 Prolactin Test
7.2.12.1 Prolactin Test Market Trends Analysis (2020-2032)
7.2.12.2 Prolactin Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.13 Insulin Test
7.2.13.1 Insulin Test Market Trends Analysis (2020-2032)
7.2.13.2 Insulin Test Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.14 Others
7.2.14.1 Others Market Trends Analysis (2020-2032)
7.2.14.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Endocrine Testing Market Segmentation, By Technology
8.1 Chapter Overview
8.2 Tandem Mass Spectrometry
8.2.1 Tandem Mass Spectrometry Market Trends Analysis (2020-2032)
8.2.2 Tandem Mass Spectrometry Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.3 Immunoassay
8.2.3.1 Immunoassay Market Trends Analysis (2020-2032)
8.2.3.2 Immunoassay Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.4 Clinical Chemistry
8.2.4.1 Clinical Chemistry Market Trends Analysis (2020-2032)
8.2.4.2 Clinical Chemistry Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.5 Monoclonal & Polyclonal Antibody Technologies
8.2.5.1 Monoclonal & Polyclonal Antibody Technologies Market Trends Analysis (2020-2032)
8.2.5.2 Monoclonal & Polyclonal Antibody Technologies Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.6 Sensor Technology
8.2.6.1 Sensor Technology Market Trends Analysis (2020-2032)
8.2.6.2 Sensor Technology Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.7 Others
8.2.7.1 Others Market Trends Analysis (2020-2032)
8.2.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Endocrine Testing Market Segmentation, By End-Use
9.1 Chapter Overview
9.2 Hospitals
9.2.1 Hospitals Market Trends Analysis (2020-2032)
9.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Ambulatory Care Centers
9.3.1 Ambulatory Care Centers Market Trends Analysis (2020-2032)
9.3.2 Ambulatory Care Centers Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Commercial Laboratories
9.4.1 Commercial Laboratories Market Trends Analysis (2020-2032)
9.4.2 Commercial Laboratories Market Size Estimates and Forecasts to 2032 (USD Billion)
9.5 Others
9.5.1 Others Market Trends Analysis (2020-2032)
9.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Endocrine Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.2.4 North America Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.2.5 North America Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.2.6.2 USA Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.2.6.3 USA Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.2.7.2 Canada Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.2.7.3 Canada Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.2.8.2 Mexico Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.2.8.3 Mexico Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Endocrine Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.1.6.2 Poland Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.1.6.3 Poland Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.1.7.2 Romania Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.1.7.3 Romania Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Endocrine Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.2.4 Western Europe Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.5 Western Europe Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.2.6.2 Germany Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.6.3 Germany Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.2.7.2 France Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.7.3 France Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.2.8.2 UK Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.8.3 UK Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.2.9.2 Italy Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.9.3 Italy Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.2.10.2 Spain Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.10.3 Spain Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.2.13.2 Austria Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.13.3 Austria Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Endocrine Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.4.4 Asia Pacific Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.5 Asia Pacific Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.4.6.2 China Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.6.3 China Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.4.7.2 India Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.7.3 India Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.4.8.2 Japan Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.8.3 Japan Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.4.9.2 South Korea Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.9.3 South Korea Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.4.10.2 Vietnam Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.10.3 Vietnam Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.4.11.2 Singapore Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.11.3 Singapore Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.4.12.2 Australia Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.12.3 Australia Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Endocrine Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.5.1.4 Middle East Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.1.5 Middle East Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.5.1.6.2 UAE Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.1.6.3 UAE Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Endocrine Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.5.2.4 Africa Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.2.5 Africa Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Endocrine Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.6.4 Latin America Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.6.5 Latin America Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.6.6.2 Brazil Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.6.6.3 Brazil Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.6.7.2 Argentina Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.6.7.3 Argentina Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.6.8.2 Colombia Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.6.8.3 Colombia Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Endocrine Testing Market Estimates and Forecasts, By Test Type (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Endocrine Testing Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Endocrine Testing Market Estimates and Forecasts, By End-Use (2020-2032) (USD Billion)
11. Company Profiles
11.1 Abbott Laboratories
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 Thermo Fisher Scientific
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Siemens Healthineers
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Roche Diagnostics
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Beckman Coulter
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 LabCorp
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Mindray
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Bio-Rad Laboratories
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Ortho Clinical Diagnostics
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 PerkinElmer.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Test Type
Estradiol (E2) Test
Follicle Stimulating Hormone (FSH) Test
Dehydroepiandrosterone Sulfate (DHEAS) Test
Human Chorionic Gonadotropin (hCG) Hormone Test
Luteinizing Hormone (LH) Test
Progesterone Test
Testosterone Test
Cortisol Test
Thyroid Stimulating Hormone (TSH) Test
Prolactin Test
Insulin Test
Others
By Technology
Tandem Mass Spectrometry
Immunoassay
Clinical Chemistry
Monoclonal & Polyclonal Antibody Technologies
Sensor Technology
Others
By End-use
Hospitals
Ambulatory Care Centers
Commercial Laboratories
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
Microbial Fermentation Technology Market was valued at $ 31.97 Bn in 2023 & is expected to reach $ 53.25 Bn by 2032, growing at a CAGR of 5.91% from 2024-2032.
The Virology Specimen Collection Market Size was valued at USD 6.09 billion in 2023 and is expected to reach USD 9.11 billion by 2032 and grow at a CAGR of 4.62% over the forecast period 2024-2032.
The global medical x-ray market is projected to reach 24.50 billion by 2032 which is anticipated to expand at a CAGR of 6.22% from 2024 to 2032.
The Behavioral Health Software Market Size was valued at USD 2.9 billion in 2023 and is expected to reach USD 11.6 billion by 2031 and grow at a CAGR of 19.0% over the forecast period 2024-2031.
Flash Chromatography Market was valued at USD 0.33 million in 2023, is projected to reach USD 0.50 million by 2032, growing at a CAGR of 4.6% from 2024 to 2032.
The Healthcare Business Intelligence (BI) Market Size was valued at USD 9.0 Billion in 2023, and is expected to reach USD 27.63 Billion by 2032, and grow at a CAGR of 14.0%.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
